A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.
Cerus Corp (CERS) reaffirmed full-year product revenue guidance of $229 million to $231 million while posting a GAAP net loss under $1 million and positive operating cash flow of $3 million.
(CERS) on Monday reported a loss of $550,000 in its third quarter.The Concord, California-based company said it had a loss of less than 1 cent on a per-share basis.
CONCORD, Calif., October 14, 2026--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from aroun
This is the newest page. Registered accounts read further back.